Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB-0,25
PKN96,4696,62,33
Msft-1,16
Nokia4,7464,792,40
IBM-0,76
Daimler AG47,4247,435-0,17
PFE0,49
21.09.2019 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 20.09.2019
Alnylam Pharm (ALNY.O, NASDAQ Cons)
Závěr k 20.9.2019 Změna (%) Změna (USD) Objem obchodů (ks)
86,50 2,25 1,90 1 279 705
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.09.2019
Popis společnosti
Obecné informace
Název společnostiAlnylam Pharmaceuticals, Inc.
TickerALNY
Kmenové akcie:Ordinary Shares
RICALNY.O
ISINUS02043Q1076
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky30.06.2019
Počet zaměstnanců k 31.01.2019 1 065
Akcie v oběhu k 31.07.2019 111 207 651
Počet akcionářů k 31.12.2018 31
MěnaUSD
Kontaktní informace
Ulice300 3rd St
MěstoCAMBRIDGE
PSČ02142-1103
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 175 518 200
Fax16175518101

Business Summary: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).
Financial Summary: BRIEF: For the six months ended 30 June 2019, Alnylam Pharmaceuticals, Inc. revenues increased 51% to $78M. Net loss before extraordinary items increased 31% to $401.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 25% to $189.9M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICPharmaceutical Preparations



  • Poslední aktualizace: 22.09.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardMichael Bonney6001.01.201601.01.2016
PresidentBarry Greene5519.09.2016
Chief Executive Officer, DirectorJohn Maraganore5612.12.2007
Chief Financial Officer, Executive Vice PresidentJeffrey Poulton5113.08.201913.08.2019
President - Research and DevelopmentAkshay Vaishnaw5607.01.2006
Chief Operating OfficerYvonne Greenstreet5619.09.2016
Chief Human Resource Officer, Senior Vice PresidentKelley Boucher-29.05.201929.05.2019
Executive Vice President, Chief Legal Officer, SecretaryLaurie Keating65
Senior Vice President, Chief Scientific OfficerKevin Fitzgerald-29.05.201929.05.2019